Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 42, 2011, Pages 17275-17280

  Wu, Tai Na ^a,b   Lin, Kun Hsien ^a,b   Chang, Ya Jen ^a   Huang, Jing Rong ^a,c   Cheng, Jing Yan ^a,d   Yu, Alice L ^a   Wong, Chi Huey ^a  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Cancer immunotherapy; Immune modulating activity; Interaction; Structure

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TERNARY COMPLEX FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CELL POLARITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS, CD1D; CELL LINE, TUMOR; CHEMOKINES; CYTOKINES; FEMALE; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HUMANS; IMMUNOTHERAPY; LIGANDS; LYMPHOCYTE ACTIVATION; MACROMOLECULAR SUBSTANCES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TH1 CELLS;

MURINAE; MUS;

EID: 80054796331     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1114255108     Document Type: Article

References (38)

1. Lantz O, Bendelac A (1994) An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 180:1097-1106. (Pubitemid 24256622)
2. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A (1994) An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med 180:1171-1176.
3. Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M (1995) Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int Immunol 7:1157-1161.
4. Davodeau F, et al. (1997) Close phenotypic and functional similarities between human and murine alphabeta T cells expressing invariant TCR alpha-chains. J Immunol 158:5603-5611. (Pubitemid 127483962)
5. Kawano T, et al. (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278:1626-1629. (Pubitemid 27516282)
6. Yoshimoto T, Paul WE (1994) CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 179:1285-1295.
7. Arase H, Arase N, Nakagawa K, Good RA, Onoe K (1993) NK1.1+ CD4+ CD8-thymocytes with specific lymphokine secretion. Eur J Immunol 23:307-310.
8. Kawakami K, et al. (2003) Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol 33:3322-3330. (Pubitemid 37541108)
9. Nieuwenhuis EE, et al. (2002) CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 8:588-593. (Pubitemid 34633436)
10. van der Vliet HJ, et al. (2004) The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 112:8-23.
11. Tahir SM, et al. (2001) Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167:4046-4050.
12. Dhodapkar MV, et al. (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667-1676. (Pubitemid 36745342)
13. Giaccone G, et al. (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702-3709. (Pubitemid 35424759)
14. Liang PH, et al. (2008) Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc 130:12348-12354.
15. Chang YJ, et al. (2007) Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci USA 104:10299-10304.
16. Schumann J, Mycko MP, Dellabona P, Casorati G, MacDonald HR (2006) Cutting edge: Influence of the TCR Vbeta domain on the selection of semi-invariant NKT cells by endogenous ligands. J Immunol 176:2064-2068. (Pubitemid 43201651)
17. Wei DG, Curran SA, Savage PB, Teyton L, Bendelac A (2006) Mechanisms imposing the Vbeta bias of Valpha14 natural killer T cells and consequences for microbial glycolipid recognition. J Exp Med 203:1197-1207. (Pubitemid 43736590)
18. Schumann J, Voyle RB, Wei BY, MacDonald HR (2003) Cutting edge: Influence of the TCR V beta domain on the avidity of CD1d:alpha-galactosylceramide binding by invariant V alpha 14 NKT cells. J Immunol 170:5815-5819. (Pubitemid 36682558)
19. Exley M, Garcia J, Balk SP, Porcelli S (1997) Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med 186:109-120. (Pubitemid 27304853)
20. Borg NA, et al. (2007) CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448:44-49. (Pubitemid 47037002)
21. Pellicci DG, et al. (2009) Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 31:47-59.
22. McCarthy C, et al. (2007) The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med 204:1131-1144. (Pubitemid 46798156)
23. Fujio M, et al. (2006) Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: Tuning the adjuvant versus immunosuppression activity. J Am Chem Soc 128:9022-9023. (Pubitemid 44078971)
24. Li X, et al. (2010) Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci USA 107:13010-13015.
25. Stanic AK, et al. (2003) Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor. J Immunol 171:4539-4551. (Pubitemid 37310569)
26. Sullivan BA, et al. (2010) Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol 184:141-153.
27. Schiefner A, Fujio M, Wu D, Wong CH, Wilson IA (2009) Structural evaluation of potent NKT cell agonists: Implications for design of novel stimulatory ligands. J Mol Biol 394:71-82.
28. Park JJ, et al. (2010) Syntheses and biological activities of KRN7000 analogues having aromatic residues in the acyl and backbone chains with varying stereochemistry. Bioorg Med Chem Lett 20:814-818.
29. Lin KH, et al. (2010) In vivo protection provided by a synthetic new alpha-galactosyl ceramide analog against bacterial and viral infections in murine models. Antimicrob Agents Chemother 54:4129-4136.
30. Berkers CR, Ovaa H (2005) Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci 26:252-257. (Pubitemid 40603073)
31. Oki S, Chiba A, Yamamura T, Miyake S (2004) The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 113:1631-1640. (Pubitemid 39071687)
32. Fujii S, et al. (2006) Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA 103:11252-11257. (Pubitemid 44156505)
33. Yu KO, et al. (2005) Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 102:3383-3388. (Pubitemid 40328054)
34. Uldrich AP, et al. (2011) A semi-invariant V(alpha)10(+) Tcell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol 12:616-623.
35. Mallevaey T, et al. (2009) T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity 31:60-71.
36. Burdin N, et al. (1998) Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol 161:3271-3281.
37. Wu D, et al. (2005) Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 102:1351-1356. (Pubitemid 40209173)
38. Ochsenreither S, et al. (2008) Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations. J Transl Med 6:1-8.